Open Access1,3-Diethylbenzimidazolium Triodide in Pharmacotherapy of Chronic Compensated Tonsillopharyngitis
Author(s) -
E. K. Meloyan,
А. В. Сафроненко,
Е. В. Ганцгорн,
L. E. Hmara,
A. O. Golubeva,
Mohammad Jabr
Publication year - 2021
Publication title -
biomedicina
Language(s) - English
Resource type - Journals
eISSN - 2713-0428
pISSN - 2074-5982
DOI - 10.33647/2074-5982-17-3-111-118
Subject(s) - pharynx , chronic pneumonia , pneumonia , pharmacotherapy , medicine , microbiology and biotechnology , antibiotics , drug resistance , gastroenterology , biology , surgery
The article presents the results of a clinical and bacteriological assessment of the pharmacological efficacy of 1,3-diethylbenzimidazolium triiodide in chronic compensated tonsillopharyngitis. As a result of a 10-day course of treatment, an improvement in the clinical status of patients was achieved, as well as a significant positive effect on the composition of the pharyngeal microbiocenosis. In particular, the content of Staphylococcus aureus, β-hemolytic streptococci, Escherichia signifi cantly decreased, and Enterobacteria, non-fermenting bacteria, and Streptococci pneumonia completely disappeared from the microbial focus. However, the conducted 10-day treatment did not lead to the complete disappearance of α-hemolytic and non-hemolytic streptococci from the microbial population. This may be explained by the reparative effect of Stellanin® on the lymphoid formations of the pharynx, contributing to the restoration of colonization resistance.